期刊
EXPERT OPINION ON EMERGING DRUGS
卷 20, 期 2, 页码 331-346出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2015.1036739
关键词
angiogenesis; bevacizumab; fallopian tube cancer; ovarian cancer; primary peritoneal cancer; tyrosine kinase inhibitors; VEGF
Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence, and overall survival remains at similar to 25%. There is a need for new treatments that can increase progression free survival and quality of life. Recent clinical trials focus on angiogenesis, VEGFs, and tyrosine kinase inhibitors that play a role in recurrence, metastasis, and ascites in EOC. Areas covered: This review summarizes clinical rationale, mechanisms of action, and clinical data for angiogenesis inhibitors under evaluation in Phase II and III trials for EOC. Anti-angiogenesis agents reviewed in this paper include aflibercept, bevacizumab, cediranib, fosbretabulin, imatinib, nintedanib, pazopanib, saracatinib, sorafenib, sunitinib, and trebananib. Expert opinion: These agents have particular rationale for potential use in EOC due to the molecular changes associated with EOC tumorigenesis, namely a significant increase in angiogenic activity. Due to the costs and toxicities associated with anti-angiogenics, biomarker or molecular signature selection strategy for patients who will most benefit would be ideal but no such strategy has been validated to date.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据